An Analysis of the Impact of Tumor Amount on the Predictive Power of a Prostate Biopsy Prognostic Assay

Faisal M. Khan, Stephen I. Fogarasi, Douglas Powell, Gerardo Fernandez, Ricardo Mesa Tejada, Michael J. Donovan

Research output: Chapter in Book/Report/Conference proceedingConference contributionpeer-review

1 Scopus citations

Abstract

The Prostate Px⊕?prognostic assay offered by Aureon Biosciences is designed to predict progression post primary treatment for prostate cancer patients based on their diagnostic biopsy specimen. The assay is driven by the automated image analysis of a diagnostic prostate needle biopsy (PNB) and incorporates pathologist acquired and digitally masked images which reflect the morphometric (Hematoxylin and Eosin, H&E) and protein expression (immunofluorescence, IF) properties of the PNB. Up to 9 images (3 H&E and 6 IF) from each of 1027 patients, with varying amounts of tumor content were included in the study. We wanted to understand what was the minimal tumor volume required to maintain assay predictive robustness as a result of overall PNB tumor content and assess the impact of pathologist tumor masking variability. 232 patients were selected who had a minimum of 80% tumor volume in a 20x magnification image. In each of the three imaging domains (2 different multiplex (Mplex) IF images and one H&E), the tumor volume was artificially reduced in increments from 80% to 2.5% of the original image area. This simulated decreasing amounts of tumor as well as variations in digital tumor masking. The univariate predictive power of individual imaging domains remained robust down to the 10% tumor level, whereas the total assay was robust through the 20% to 10% tumor level. This work presents one of the first assessments of the variety in tumor amounts on the predictive power of a commercially available prognostic assay that is reliant on multiple bioimaging domains.

Original languageEnglish
Title of host publicationMedical Imaging 2011
Subtitle of host publicationImage Perception, Observer Performance, and Technology Assessment
DOIs
StatePublished - 2011
Externally publishedYes
EventMedical Imaging 2011: Image Perception, Observer Performance, and Technology Assessment - Lake Buena Vista, FL, United States
Duration: 16 Feb 201117 Feb 2011

Publication series

NameProgress in Biomedical Optics and Imaging - Proceedings of SPIE
Volume7966
ISSN (Print)1605-7422

Conference

ConferenceMedical Imaging 2011: Image Perception, Observer Performance, and Technology Assessment
Country/TerritoryUnited States
CityLake Buena Vista, FL
Period16/02/1117/02/11

Keywords

  • Image variability
  • Prognostic assay
  • Prostate biopsy
  • Tumor variability
  • Tumor volume

Fingerprint

Dive into the research topics of 'An Analysis of the Impact of Tumor Amount on the Predictive Power of a Prostate Biopsy Prognostic Assay'. Together they form a unique fingerprint.

Cite this